kabutan

DAIICHI SANKYO COMPANY, LIMITED(4568) Summary

4568
TSE Prime
DAIICHI SANKYO COMPANY, LIMITED
3,653.0
JPY
+11.0
(+0.30%)
Jul 30, 3:30 pm JST
24.68
USD
Jul 30, 2:30 am EDT
Result
PTS
outside of trading hours
3,670
Jul 30, 11:22 pm JST
Summary Chart Historical News Financial Result
PER
22.6
PBR
4.19
Yield
2.14%
Margin Trading Ratio
13.74
Stock Price
Jul 30, 2025
Opening Jul 30, 9:00 am
3,652.0 JPY 24.60 USD
Previous Close Jul 29
3,642.0 JPY 24.56 USD
High Jul 30, 12:37 pm
3,692.0 JPY 24.95 USD
Low Jul 30, 10:08 am
3,611.0 JPY 24.33 USD
Volume
5,216,400
Trading Value
0.02T JPY 0.13B USD
VWAP
3648.08 JPY 24.65 USD
Minimum Trading Value
365,300 JPY 2,468 USD
Market Cap
6.92T JPY 0.05T USD
Number of Trades
6,303
Liquidity & Number of Trades
As of Jul 30, 2025
Liquidity
High
1-Year Average
9,460
1-Year High Apr 25, 2025
29,113
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jul 25, 2025 255,500 3,395,200 13.29
Jul 18, 2025 248,000 3,832,900 15.46
Jul 11, 2025 196,200 4,793,600 24.43
Jul 4, 2025 192,200 4,607,900 23.97
Jun 27, 2025 170,300 4,524,300 26.57
Company Profile
DAIICHI SANKYO COMPANY, LIMITED is a major pharmaceutical company in Japan, with strengths in cardiovascular and infectious diseases. The company has partnered with AstraZeneca of the UK for new cancer drugs.
Sector
Pharmaceuticals
DAIICHI SANKYO COMPANY, LIMITED primarily engages in the research, development, manufacturing, and sales of pharmaceuticals, with a broad range of operations both domestically and internationally. In Japan, the company operates through multiple subsidiaries involved in pharmaceutical manufacturing, research and development and sales of over-the-counter drugs, and vaccine research, development, and production, showcasing a diverse group of companies with varied functions. The company has partnered with AstraZeneca in the oncology field. Internationally, DAIICHI SANKYO has subsidiaries in the United States, Europe, China, Brazil, and other regions, conducting pharmaceutical research, development, manufacturing, and sales in each area. In the United States, the company has established a holding company, while in Europe, it operates through numerous group companies across various countries. DAIICHI SANKYO leverages its global network for research, development, manufacturing, and sales to enhance its competitiveness in the world market.